BioCryst (BCRX) director receives stock grants and options, updates trust holdings

Rhea-AI Filing Summary

BIOCRYST PHARMACEUTICALS INC director Steven K. Galson reported equity awards and updated holdings. He received 15,294 shares of Common Stock as a grant of Restricted Stock Units under the company’s Non-Employee Director Compensation Policy, with these units scheduled to vest on the first anniversary of the grant date.

He also received an automatic stock option grant covering 33,540 shares of Common Stock at an exercise price of $8.50 per share, exercisable from June 11, 2027 and expiring June 11, 2036. Following these awards, he holds 27,794 Common shares directly and 58,371 Common shares indirectly through a living trust. The filing reflects compensation-related grants rather than open-market purchases or sales.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Galson Steven K

Role null

Type	Security	Shares	Price	Value
Grant/Award	Automatic Stock Option Grant	33,540	$0.00	--
Grant/Award	Common Stock	15,294	$0.00	--
holding	Common Stock	--	--	--

Holdings After Transaction: Automatic Stock Option Grant — 33,540 shares (Direct, null); Common Stock — 27,794 shares (Direct, null); Common Stock — 58,371 shares (Indirect, By Trust)

Footnotes (1)

1. Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. On July 23, 2025, the Reporting Person transferred 12,491 shares to a living trust for no consideration. The Reporting Person is an indirect beneficial owner of the shares held by the trust. Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.

Key Figures

RSU grant: 15,294 shares Stock option grant size: 33,540 shares Option exercise price: $8.50 per share +4 more

7 metrics

RSU grant 15,294 shares Restricted Stock Units granted June 11, 2026; vest on first anniversary

Stock option grant size 33,540 shares Automatic stock option grant on June 11, 2026

Option exercise price $8.50 per share Exercise price for Automatic Stock Option Grant

Option exercisability date June 11, 2027 Date options become exercisable

Option expiration date June 11, 2036 Expiration of Automatic Stock Option Grant

Direct common shares after grant 27,794 shares Total direct Common Stock holdings after RSU grant

Indirect common shares via trust 58,371 shares Common Stock held indirectly through a living trust

Key Terms

Restricted Stock Units, Automatic Stock Option Grant, Non-Employee Director Compensation Policy, indirect beneficial owner, +1 more

5 terms

Restricted Stock Units financial

"Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Automatic Stock Option Grant financial

"Automatic Stock Option Grant with an exercise price of 8.5000 and expiration date of 2036-06-11"

Non-Employee Director Compensation Policy financial

"pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended"

indirect beneficial owner financial

"The Reporting Person is an indirect beneficial owner of the shares held by the trust."

living trust financial

"transferred 12,491 shares to a living trust for no consideration"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Galson Steven K

(Last) (First) (Middle)

4505 EMPEROR BLVD.

SUITE 200

(Street)

DURHAM NORTH CAROLINA 27703

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOCRYST PHARMACEUTICALS INC [ BCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/11/2026		A		15,294(1)	A	$0	27,794	D
Common Stock								58,371(2)	I	By Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Automatic Stock Option Grant(3)	$8.5	06/11/2026		A		33,540		06/11/2027	06/11/2036	Common Stock	33,540	$0	33,540	D

Explanation of Responses:

1. Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.

2. On July 23, 2025, the Reporting Person transferred 12,491 shares to a living trust for no consideration. The Reporting Person is an indirect beneficial owner of the shares held by the trust.

3. Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.

	/s/ Alane P. Barnes, by power of attorney	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did BCRX director Steven K. Galson report in this Form 4?

He reported equity compensation awards and updated holdings. The filing shows grants of Restricted Stock Units and stock options, plus his direct and indirect Common Stock ownership, without any open-market purchases or sales disclosed.

How many BCRX Restricted Stock Units did Steven K. Galson receive?

He received 15,294 shares of Common Stock as a grant of Restricted Stock Units. These RSUs were issued under BioCryst’s Non-Employee Director Compensation Policy and are scheduled to vest on the first anniversary of the June 11, 2026 grant date.

What are the terms of Steven K. Galson’s new BCRX stock options?

He was granted options on 33,540 shares of Common Stock at an exercise price of $8.50 per share. These options become exercisable on June 11, 2027 and expire on June 11, 2036, according to the Form 4 disclosure.

How many BCRX shares does Steven K. Galson hold after these transactions?

After the reported transactions, he holds 27,794 shares of Common Stock directly. He also is an indirect beneficial owner of 58,371 shares held by a living trust, as reflected in the Form 4 reporting structure.

Were there any open-market trades by Steven K. Galson in BCRX shares?

No open-market trades are reported. The Form 4 shows compensation-related acquisitions, including Restricted Stock Units and stock options, and a holdings entry for shares in a trust, without any purchases or sales on the open market.

What is the role of the living trust in Steven K. Galson’s BCRX holdings?

A living trust holds 58,371 BCRX Common shares, for which he is reported as an indirect beneficial owner. A prior transfer of 12,491 shares into the trust for no consideration is noted in a footnote, clarifying the indirect ownership structure.